What is semaglutide, the medication in Ozempic and Wegovy?

Semaglutide is a GLP-1 medication: it attaches to the GLP-1 receptor and switches it on. It is the medication in Ozempic and Rybelsus, approved for adults with type 2 diabetes, and in Wegovy, approved for reducing excess weight and lowering the risk of major cardiovascular events in certain people (Wegovy prescribing information; Ozempic prescribing information; Rybelsus and Ozempic tablets prescribing information).

This guide explains published facts and prices. It is not medical advice: a licensed provider who knows your health history decides what is right for you.

Is semaglutide the same as Ozempic?

Ozempic is one brand of semaglutide. Wegovy and Rybelsus are others, and each brand's label lists its own approved uses:

So "semaglutide" on a price list does not tell you which brand it is, or whether it is a brand at all. Ask.

How is semaglutide taken?

The Wegovy label sets out its schedule like this (Wegovy prescribing information):

Ozempic and Rybelsus have their own labels, so ask your provider for the schedule of the product you are prescribed, and what comes after the first 30 days of tablets.

What did the semaglutide weight loss trial find?

In a trial published in 2021, 1,961 adults without diabetes were randomly assigned, two to one, to 68 weeks of once-weekly semaglutide 2.4 mg injections under the skin or a placebo, with a lifestyle program for both groups. Each had a body-mass index (BMI) of 30 or more, or 27 or more with at least one weight-related health condition (New England Journal of Medicine, 2021).

By week 68, people on semaglutide had lost an average of 14.9% of their starting body weight, compared with 2.4% on placebo. Nausea and diarrhea were the most common side effects with semaglutide; they were usually short-lived and mild to moderate, and they eased with time (New England Journal of Medicine, 2021).

An average is not a forecast for one person. Ask your provider what the results mean for you.

Is semaglutide safe?

The Wegovy label answers with facts, not a yes or a no: who it is approved for, which is above, and these warnings, which a licensed provider weighs for you (Wegovy prescribing information):

The label's most common side effects, reported in at least 5% of adults or children 12 and older, are nausea, diarrhea, vomiting, constipation, abdominal pain, dysesthesia (unpleasant, abnormal sensations), headache, fatigue, indigestion, dizziness, bloating, burping, low blood sugar in people with type 2 diabetes, gas, gastroenteritis (inflammation of the stomach and intestines), acid reflux and hair loss (Wegovy prescribing information).

What about compounded semaglutide?

A med spa's monthly semaglutide price may not be for Ozempic, Wegovy or Rybelsus. FDA has raised these concerns about semaglutide in particular (FDA's concerns with unapproved GLP-1 drugs):

So ask whether the product is FDA approved or compounded, which form of semaglutide it contains, how each dose is measured, and where the medication comes from. FDA's broader concerns about compounded and unapproved GLP-1 drugs are in what is a GLP-1.

What does semaglutide cost at a Georgia med spa?

These are estimates from what Georgia med spas and skin clinics publish, not quotes, and we do not name any company.

For how semaglutide compares with tirzepatide, in price and in the research, read semaglutide or tirzepatide.

Questions to ask your provider

Ask for the brand or product name and each month's price in writing before you start.

Sources

  1. Wegovy (semaglutide) injection and tablets, FDA-approved prescribing information (Novo Nordisk, label effective June 2026), DailyMed, National Library of Medicine
  2. Ozempic (semaglutide) injection, FDA-approved prescribing information (Novo Nordisk, label effective June 2026), DailyMed, National Library of Medicine
  3. Rybelsus and Ozempic (oral semaglutide) tablets, FDA-approved prescribing information (Novo Nordisk, label effective January 2026), DailyMed, National Library of Medicine
  4. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021;384(11):989-1002
  5. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss, U.S. Food and Drug Administration

Prices mentioned here come from our Georgia med spa cost ranges, built from the prices and cost guides Georgia med spas publish on their public websites, collected September and October 2026.

Find a Georgia med spa